Pharmacotherapy of dyslipidemia
-
Upload
dr-irfan-ahmad-khan -
Category
Health & Medicine
-
view
81 -
download
4
Transcript of Pharmacotherapy of dyslipidemia
![Page 1: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/1.jpg)
Pharmacotherapy of Dyslipidemia
Dr. Irfan Ahmad KhanSenior Resident
![Page 2: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/2.jpg)
Introduction
• Dyslipidemia – disorders of lipoprotein metabolism.– Abnormal plasma cholesterol and/or Triglyceride (TG)
concentrations.
• Major cause of atherosclerosis and related cardiovascular diseases.
![Page 3: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/3.jpg)
Lipoprotein
![Page 4: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/4.jpg)
Major lipoprotein classes
Chylomicron remnants
<1.006 Dietary triglycerides and cholesterol
TG<CE B-48, E, A-I, A-V, C-I, C-II, C-III
Product of Chylomicron metabolism
apoE-mediated uptake by liver
A-V
A-IV, A-V
IDL
![Page 5: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/5.jpg)
Inhibits LPL activity and lipoprotein binding to receptors
![Page 6: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/6.jpg)
Lipoprotein metabolism
• Transport of Dietary Lipids / Exogenous Pathway
• Transport of Hepatic Lipids / Endogenous Pathway
• Reverse Cholesterol Transport
![Page 7: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/7.jpg)
+
50%
50%75%
NPC1L1
ACAT-2 ACAT-2
HL
![Page 8: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/8.jpg)
Reverse Cholesterol Transport
ABCA1TG HL
![Page 9: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/9.jpg)
![Page 10: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/10.jpg)
Hyperlipidemia
Primary
Secondary
Monogenic Polygenic/multifactorialMutation in
apolipoproteins, their
receptors, transport
mechanism, metabolizing
enzyme
Diificult to t/t
• Multiple genetic
• Dietary
• Physical activity
related causes
• DM• Nephrotic
Syndrome• Hypothroidism• Alcoholism• Drugs
(Corticosteroids, oral contraceptives)
![Page 11: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/11.jpg)
(I)
(III)
(IIa)
![Page 12: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/12.jpg)
Polygenic/Multifactorial
• IIb: Familial Combined (Polygenic)Hyperlipidemia– Similar to IIa except VLDL ed– Deficiency of LDL receptors and overproduction of VLDL by liver
• IV: Familial Hypertriglyceridemia– Overproduction and/ or decreased removal of VLDL
![Page 13: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/13.jpg)
Treatment strategies
1. Dietary and lifestyle modification (NCEP-ATP 4 guidelines)• Aerobic exercise or brisk walking (20-60 min/d for 3-5 days/week)• Reduce intake of cholesterol(<30% of total calories) and saturated
fats(5-6% of total calories)• Reduce sugary beverage intake (<36 oz/wk), sweets• Cessation of alcohol and smoking
2. Drugs
• Individualized approach
![Page 14: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/14.jpg)
Drugs for dyslipidemia
A. Well established Anti-dyslipidemic therapies– HMG-CoA (3-hydroxy-3- methyl glutaryl CoA) reductase inhibitors– Fibric acid derivatives– Bile acid sequestrants– Nicotinic acid– Inhibitor of dietary cholesterol uptake
B. Newly developed Anti-dyslipidemic therapies– Proprotein Convertase Subtilisin/Kexin Type 9(PCSK9) inhibitors– Inhibitor of ApoB Synthesis– Microsomal Triglyceride Transfer Protein (MTP) inhibitors– ApoC-III Synthesis inhibitors– Gugulipid and fish oil derivatives
![Page 15: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/15.jpg)
• Most effective, best-tolerated
• Agents included
• Lovastatin
• Pravastatin
• Simvastatin
• Atorvastatin
• Fluvastatin
• Rosuvastatin
HMG-CoA Reductase Inhibitors (statins)
![Page 16: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/16.jpg)
MOAInhibit HMG-CoA reductase competitively
(HMG-CoAMevalonic acid)
Inhibit biosynthesis of cholesterol
Depletion of cholesterol in hepatocytes
Activates Scap (SREBP cleavage activating protein)
Proteolytic cleavage of SREBP (Sterol regulatory element binding protein)
Translocates to nucleus
LDL-R expression on hepatocytes
ed hepatic uptake of LDL, IDL & decrease plasma LDL (20-55% )
(Major effect – dose and agent dependent6% reduction with doubling of dose)
![Page 17: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/17.jpg)
Decrease VLDL by :• ↓ hepatic VLDL synthesis d/t ↓ in cholesterol ↓LDL-C(~25%) Homozygous familial hypercholesterolemia (LDLR are absent)
Effect on TGs :
1. If TGs >250 mg/dL - % decrease ~ % decrease in LDL-C
2. If TGs <250 mg/dL - < 25% decrease in TG levels
in HDL ~15-20% (Rosuvastatin)
![Page 18: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/18.jpg)
Pleiotropic effects:
• Improved endothelial function , NO
• Increase plaque stability
• Reduce lipoprotein oxidation
• Anti inflammatory role, ↓ CRP
• Reduce platelet aggregation, profibrinolytic activity
![Page 19: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/19.jpg)
Pharmacokinetics
• Extensive first pass hepatic metabolism (uptake by OATP1B1)
• Simvastatin, Lovastatin : lactone prodrugs
• t1/2-1-4 hrs taken in evening Atorvastatin, Rosuvastatin (~20 hrs), Simvastatin (~12 hrs).
Dosing
• advisable to start each patient on a dose that will achieve the
patient's target goal for LDL-C lowering
![Page 20: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/20.jpg)
Statins dose (mg) Required to Achieve Various Reductions in LDL-C from Baseline
![Page 21: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/21.jpg)
Adverse effects
• Myopathy: o Myopathy–rhabdomyolysis–myoglobinuria–renal shut downo High dose / Old age/ Perioperative periodo Hepatic/ renal dysfunction, Hypothyroidismo Drugs: fibrates, especially gemfibrozil (OATP1B1 inhibition,
interferes with glucuronidation), erythromycin, cyclosporine, itraconazole (CYP3A4)
o Fluvastatin (2C9) and pravastatin (unchanged) – less risk of myopathy
o Niacinenhanced inhibition of skeletal muscle cholesterol synthesis
![Page 22: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/22.jpg)
• Hepatotoxicity :
• Elevation of transaminases.
• Severe hepatitis rare
• Monitoring recommended before starting therapy and at 2-3
months, then annually.
C/I : pregnancy & lactation.
• Pravastatin in children >8 yrs.
• Atorvastatin, Simvastatin and Lovastatin >11 yrs.
![Page 23: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/23.jpg)
Use
• DOC for hypercholesterolemia
• Statins + Niacin = ed effectiveness but risk of myopathy
• Statins + resins = 20-30% greater reduction in LDL-C
• Statins + fibrates = useful when LDL associated with TG
• Atorvastatin and Rosuvastatin : max TG lowering effect
• Statin + resins + Niacin = 70% reduction in LDL-C
• Simvastatin + Ezetimibe = 60% reduction in LDL-C
![Page 24: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/24.jpg)
Activators of PPARα – gene transcription regulator (expressed
primarily in liver and brown adipose tissue)
!st generation - Gemfibrozil (600-mg BD, 30 minutes
before morning and evening meals)
2nd generation - Clofibrate (~500 mg QID)
Fenofibrate (~145 mg OD)
Bezafibrate( ~200 mg TDS)
Fibric Acid Derivatives
![Page 25: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/25.jpg)
MOA
• LPL synthesis : clearance of TG-rich lipoproteins
• Reduce expression of apoC-III (an inhibitor of lipolytic processing
and R-mediated clearance) thereby clearance of VLDL
• Reduce TGs (upto 50%) by stimulation of fatty acid oxidation
• in HDL-C(~15%): stimulation of apoA-I & apoA-II expression
• Misc. effect : inhibition of coagulation and fibrinolysis
![Page 26: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/26.jpg)
Therapeutic Uses
• DOC
– Type III familial dysbetalipoproteinemia
– Severe hypertriglyceridemia
– Chylomicronemia syndrome
• Familial hypercholesterolemia type IIa
• Familial combined hypercholesterolemia type IIb
• triglycerides and low HDL-C levels associated with the metabolic
syndrome or type 2 diabetes mellitus
![Page 27: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/27.jpg)
Adverse effects
• Abdominal discomfort/ Diarrhea/ Nausea.
• Increased risk of gallstones (clofibrate).
• Prolonged prothrombin time
• Myopathy :
• high risk when combined with statins (followed at 3 months).
• Gemfibrozil : highest incidence.
• Fenofibrate safer: glucuronidated by enzymes that are not
involved in statin glucuronidation
C/I
• Children & pregnant women
• Renal failure
![Page 28: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/28.jpg)
• Safest as not absorbed from intestine
• Cholestyramine, colestipol, colesevelam
• MOA:
– Highly positively charged molecules that bind negatively
charged bile acids
– Due to large size, resins are not absorbed and bound bile acids
are excreted in stool
– Pool of bile acids is depleted
Bile Acid Sequestrants
![Page 29: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/29.jpg)
![Page 30: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/30.jpg)
• The resin-induced decrease in BA is a/w in hepatic TG
synthesis. Monitoring (every 1-2 weeks) of fasting TG levels is
needed or their use in such patients should be avoided.
• 12-18% reduction in LDL-C.
• 40 – 60% reduction in LDL-C when used along with statin/ niacin
• 4-5% rise in HDL-C.
![Page 31: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/31.jpg)
Therapeutic Uses:
• Heterozygous familial hypercholesterolemia
• Drug of choice for children and females in reproductive age group.
Dose :
• Cholestyramine 4g packet
• Colestipol 5g packet / 1g tab.
• Colesevelam 1.875 g packet/ 625 mg tab. (3 tab.)BD with meal
C/I- Hypertriglyceridemia
Mixed with water or juice. Ideally, patient should take resins BBF and before supper, starting with one packet twice daily
![Page 32: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/32.jpg)
Adverse effects
• Heart burn, dyspepsia, bloating, gritty sensation (suspending
powder in liquid several hours before ingestion)
• Malabsorption of Vitamin K, folic acid etc.
• Constipation (adequate water intake and psyllium)
• Rarely can cause hyperchloremic acidosis.
D/I:
• Binds to digoxin, warfarin, thyroxine, some statins, furosemide,
thiazides; prevents absorption 1 hr before or 3-4 hrs after bile
acid sequestrants.
![Page 33: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/33.jpg)
Niacin (Nicotinic Acid)
• Oldest, effective, inexpensive, often used in combination
• Best agent available for increasing HDL-C (25-30%)
• Lowers TGs (40%), LDL-C (20-25%) in dose of 1.5-3 g/day
• Reduces Lp(a) levels significantly.
![Page 34: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/34.jpg)
• LPL activity, clearance of chylomicrons and VLDL
• Inhibit a rate-limiting enzyme of TG synthesis, Diacyl Glycerol Acyl Transferase-2
Inhibits lipolysis of TGs by HS Lipases by inhibiting adipocyte adenylyl cyclase
Decrease fractional clearance of
Stimulates expression of SR-CD36 & ABCA1
1.
2.
3.
4.
![Page 35: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/35.jpg)
Therapeutic uses:
• Hypertriglyceridemia and high LDL-C associated with low HDL
• DOC for Familial combined hypertriglyceridemia
• Familial dysbetalipoproteinemia (type 3)
• Severe mixed hypertriglyceridemia(type 4)
• Heterozygous familial hypercholesterolemia (+ resins/statins)
Niacin Starting Dose Maximal Dose
Immediate release 100 mg TDS 1 g TDS
Sustained release 250 mg BD 1.5 g BD
Extended release 500 mg HS 2 g HS
![Page 36: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/36.jpg)
Side effects
• Flushing, warmth (PGD2 & E2)
• Pruritus, rashes
• Dyspepsia
• Skin dryness
• Acanthosis nigricans
• Liver dysfunction (flu like fatigue)
• Hyperglycemia, Hyperuricemia
• Risk of myopathy if combined with
statins. (dose not >25% of
maximum)
C/I• Peptic ulcer disease
• Gout
• DM
• Pregnancy
![Page 37: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/37.jpg)
Ezetimibe
• Inhibition of cholesterol absorption by jejunal enterocytes (NPC1L1
transport protein) decrease in hepatic cholesterol upregulation
of LDL-R.
• Lowers LDL-C by 15-20%
• HDL-C by ~2% and decrease TGs by ~5%
• 10 mg tablet/day with statins
• Bile-acid sequestrants inhibit absorption of ezetimibeshould not be
co-administered
• ADRs: rare allergic reactions
![Page 38: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/38.jpg)
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors
• PCSK9: physiological enzyme ligand of LDL-R
Low pH Prevents dissociation
![Page 39: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/39.jpg)
• Alirocumab & Evolocumab (Approved in 2015)– Heterozygous FH– Lower LDL-C by 50-72% (effect persists for 2-4 weeks after
single S.C. injection)– Lower PCSK9 activity upto 80%; Reduce Lp(a)– Alirocumab: 75 mg SC q2weeks; If the LDL-C lowering response
is inadequate, may increase to 150 mg SC q2weeks– Evolocumab: 140 mg SC q2weeks
• Bococizumab (Phase III)
• PCSK9 also involved in degradation of many receptors that are also receptors for viruses (human rhinovirus and hepatitis C virus) viral infections need to be monitored in patients on PCSK9 inhibitors
![Page 40: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/40.jpg)
Inhibitor of ApoB Synthesis: Mipomersen
• Antisense oligonucleotide that inhibits ApoB-100 synthesis in liver decrease VLDL & LDL-C
• Useful in heterozygous and homozygous FH who lack LDL-R
• 200 mg SC weekly: reduces apoB(33-54%), LDL-C(34-52%), Lp(a)(24%)
• ADRs: severe injection site reaction, flu-like reactions, headache, hepatotoxicity
• Approved for t/t of homozygous FH with restriction due to hepatotoxicity available through restricted Risk Evaluation & Mitigation Strategy(REMS) program
![Page 41: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/41.jpg)
Microsomal Triglyceride Transfer Protein (MTP) inhibitors: Lomitapide
• Bind and inhibit MTP from transferring TG to apoB in liver decrease in VLDL & LDL-C
• Useful in homozygous FH who lack LDL-R
• Reduces LDL-C (42-50%)
• Dose: Initially orally 5mg/day 10, 20 40 upto 60 mg
• Approved for t/t of homozygous FH with restriction hepatotoxicity available through restricted Risk Evaluation & Mitigation Strategy(REMS) program
![Page 42: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/42.jpg)
ApoC-III Synthesis inhibitors: Volanesorsen
• ApoC-III inhibits LPL reduced lipolysis of TG rich lipoproteinsTG
• ApoC-III Inhibits hepatic lipase reduced catabolism and uptake of TG rich lipoprotein remnants
• Phase 3 : hypertriglyceridemia, familial chylomicronemia syndrome
![Page 43: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/43.jpg)
Gugulipid
• Developed at CDRI, Lucknow
• MOA: inhibits CH biosynthesis and enhances rate of excretion of CH
• Dose: 25 mg TDS orally
• ADR: Loose stools
![Page 44: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/44.jpg)
Fish oil derivatives (Omega-3 Fatty Acids)
• Contains PUFAs: eicosa penta-enoic acid (EPA) and docosa hexa-enoic acid (DHA)
• TG catabolism, membrane stabilizing and anti-oxidant action
• 4g/day
![Page 45: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/45.jpg)
![Page 46: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/46.jpg)
![Page 47: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/47.jpg)
![Page 48: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/48.jpg)
![Page 49: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/49.jpg)
Thank you
![Page 50: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/50.jpg)
Disorders of reduced HDL-C
• Gene deletion in APO A5-A1-C3-A4 locus and coding mutation in APOA1
• Tangier Disease (ABCA1 deficiency)
• Familial LCAT deficiency
![Page 51: Pharmacotherapy of dyslipidemia](https://reader036.fdocuments.us/reader036/viewer/2022062302/58ed7c111a28ab726b8b4665/html5/thumbnails/51.jpg)
2. Therapies that HDL
– Cholestryl ester transfer protein (CETP) Inhibitors: Dalcetrapib, Torcetrapib, Evacetrapib, Anacetrapib